suramin has been researched along with Diabetes Mellitus, Type 2 in 2 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin treatment significantly suppressed the increase in the urinary albumin-to-creatinine ratio, glomerular hypertrophy, mesangial matrix expansion, and glomerular fibrosis in KK-Ay mice." | 1.91 | Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice. ( Kodera, R; Miyamoto, S; Oda, K; Shikata, K; Wada, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oda, K | 1 |
| Miyamoto, S | 1 |
| Kodera, R | 1 |
| Wada, J | 1 |
| Shikata, K | 1 |
| Korrapati, MC | 1 |
| Howell, LA | 1 |
| Howell, LH | 1 |
| Shaner, BE | 1 |
| Megyesi, JK | 1 |
| Siskind, LJ | 1 |
| Schnellmann, RG | 1 |
2 other studies available for suramin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Suramin prevents the development of diabetic kidney disease by inhibiting NLRP3 inflammasome activation in KK-Ay mice.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Inflammasomes; I | 2023 |
Suramin: a potential therapy for diabetic nephropathy.
Topics: Actins; Animals; Collagen Type I; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, | 2013 |